Phase 2Data readout

Bremelanotide + PDE5i

Erectile dysfunction

PTNPalatin Technologies

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: Bremelanotide + PDE5i
Development stage: Phase 2
Event type: Data readout
Indication: Erectile dysfunction

Research summary

What is being tracked?

This catalyst tracks a Phase 2 data readout for Bremelanotide + PDE5i in Erectile dysfunction . The expected timing is based on the latest available company guidance and may change.

Development notes

10/1/24 - PK study to start in Q1 2025 and Ph2/3 study in H2 2025 w/ topline data in H1 '26. 11/13/25:- PR No update. 02/17/26:- PR No update. 05/13/26:- PR No update.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Source URL not provided